| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Lymphoma, T-Cell, Cutaneous | 11 | 2020 | 121 | 4.74 | Why? |
| Skin Neoplasms | 34 | 2020 | 1679 | 4.07 | Why? |
| Mycosis Fungoides | 8 | 2019 | 48 | 1.92 | Why? |
| Receptors, KIR3DL2 | 7 | 2019 | 7 | 1.89 | Why? |
| Sezary Syndrome | 8 | 2018 | 30 | 1.47 | Why? |
| Penile Neoplasms | 3 | 2018 | 97 | 0.98 | Why? |
| Leukemia-Lymphoma, Adult T-Cell | 2 | 2018 | 28 | 0.92 | Why? |
| Carcinoma in Situ | 2 | 2018 | 58 | 0.88 | Why? |
| Lymphoma, Follicular | 2 | 2019 | 109 | 0.87 | Why? |
| Skin | 14 | 2019 | 2096 | 0.83 | Why? |
| Bowen's Disease | 2 | 2018 | 14 | 0.79 | Why? |
| Hypercalcemia | 1 | 2019 | 40 | 0.77 | Why? |
| Epidermodysplasia Verruciformis | 1 | 2018 | 7 | 0.74 | Why? |
| Lymphomatoid Papulosis | 1 | 2017 | 11 | 0.73 | Why? |
| Lymphoma, T-Cell | 1 | 2018 | 70 | 0.71 | Why? |
| Doxorubicin | 2 | 2017 | 313 | 0.71 | Why? |
| Lymphoma, Large-Cell, Anaplastic | 1 | 2017 | 24 | 0.70 | Why? |
| Thalidomide | 2 | 2018 | 247 | 0.69 | Why? |
| Seminoma | 1 | 2017 | 16 | 0.69 | Why? |
| Protein-Tyrosine Kinases | 1 | 2018 | 158 | 0.64 | Why? |
| Cytoreduction Surgical Procedures | 1 | 2017 | 144 | 0.63 | Why? |
| Neoplasms, Second Primary | 1 | 2017 | 100 | 0.63 | Why? |
| Testicular Neoplasms | 1 | 2017 | 91 | 0.61 | Why? |
| Antineoplastic Agents, Immunological | 2 | 2019 | 830 | 0.57 | Why? |
| Urticaria | 2 | 2017 | 472 | 0.53 | Why? |
| Angiogenesis Inhibitors | 1 | 2017 | 395 | 0.50 | Why? |
| Dermatologic Agents | 5 | 2018 | 489 | 0.49 | Why? |
| Radiopharmaceuticals | 1 | 2017 | 763 | 0.47 | Why? |
| Positron-Emission Tomography | 1 | 2017 | 802 | 0.46 | Why? |
| Scleroderma, Localized | 4 | 2017 | 25 | 0.43 | Why? |
| Melanoma | 6 | 2019 | 1229 | 0.43 | Why? |
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2019 | 877 | 0.42 | Why? |
| Chilblains | 4 | 2021 | 1156 | 0.40 | Why? |
| Fluorodeoxyglucose F18 | 1 | 2017 | 1153 | 0.40 | Why? |
| Graft vs Host Disease | 3 | 2018 | 501 | 0.38 | Why? |
| Paraneoplastic Syndromes | 2 | 2019 | 28 | 0.38 | Why? |
| Pyoderma Gangrenosum | 2 | 2018 | 41 | 0.37 | Why? |
| Penile Diseases | 2 | 2018 | 15 | 0.37 | Why? |
| Neoplasm Staging | 8 | 2018 | 1999 | 0.36 | Why? |
| Tetrahydronaphthalenes | 1 | 2008 | 32 | 0.36 | Why? |
| Still's Disease, Adult-Onset | 2 | 2018 | 100 | 0.33 | Why? |
| Neoplasm Recurrence, Local | 6 | 2019 | 1063 | 0.33 | Why? |
| Lupus Erythematosus, Cutaneous | 2 | 2018 | 104 | 0.32 | Why? |
| Antibiotics, Antineoplastic | 2 | 2017 | 128 | 0.32 | Why? |
| Antineoplastic Agents | 5 | 2019 | 3550 | 0.31 | Why? |
| Pemphigus | 2 | 2019 | 163 | 0.30 | Why? |
| Lymphoma, Large B-Cell, Diffuse | 2 | 2018 | 176 | 0.30 | Why? |
| Skin Diseases | 5 | 2020 | 2509 | 0.30 | Why? |
| Programmed Cell Death 1 Receptor | 3 | 2019 | 724 | 0.29 | Why? |
| Drug Substitution | 2 | 2018 | 385 | 0.28 | Why? |
| Infliximab | 2 | 2018 | 502 | 0.27 | Why? |
| Dermatologists | 2 | 2019 | 435 | 0.25 | Why? |
| Drug Resistance, Neoplasm | 3 | 2019 | 447 | 0.25 | Why? |
| Castleman Disease | 2 | 2019 | 28 | 0.23 | Why? |
| Methotrexate | 3 | 2019 | 471 | 0.23 | Why? |
| Granuloma | 2 | 2017 | 88 | 0.23 | Why? |
| Diagnosis, Differential | 12 | 2019 | 7220 | 0.23 | Why? |
| Vasculitis | 2 | 2019 | 691 | 0.22 | Why? |
| Male | 63 | 2020 | 367725 | 0.22 | Why? |
| Dermatitis, Atopic | 2 | 2019 | 714 | 0.21 | Why? |
| Histone Deacetylase Inhibitors | 2 | 2018 | 79 | 0.21 | Why? |
| Erysipelas | 1 | 2019 | 5 | 0.21 | Why? |
| Etanercept | 2 | 2018 | 162 | 0.21 | Why? |
| Biopsy | 7 | 2019 | 2811 | 0.21 | Why? |
| Disease-Free Survival | 4 | 2018 | 1654 | 0.21 | Why? |
| Humans | 96 | 2021 | 930598 | 0.20 | Why? |
| Maximum Tolerated Dose | 1 | 2019 | 65 | 0.20 | Why? |
| Keratoderma, Palmoplantar | 1 | 2019 | 24 | 0.20 | Why? |
| Paris | 3 | 2018 | 1287 | 0.20 | Why? |
| Fingers | 2 | 2019 | 221 | 0.20 | Why? |
| Prurigo | 1 | 2019 | 17 | 0.20 | Why? |
| Skin Diseases, Vascular | 1 | 2020 | 69 | 0.20 | Why? |
| Serum Sickness | 1 | 2018 | 3 | 0.20 | Why? |
| Leg | 2 | 2018 | 142 | 0.20 | Why? |
| Desmoglein 1 | 1 | 2018 | 9 | 0.19 | Why? |
| Fractures, Closed | 1 | 2018 | 13 | 0.19 | Why? |
| Interleukin-4 Receptor alpha Subunit | 1 | 2019 | 46 | 0.19 | Why? |
| GATA2 Transcription Factor | 1 | 2018 | 13 | 0.19 | Why? |
| Pancreatitis, Alcoholic | 1 | 2018 | 4 | 0.19 | Why? |
| Apyrase | 1 | 2019 | 39 | 0.19 | Why? |
| Anilides | 1 | 2019 | 105 | 0.19 | Why? |
| Cutis Laxa | 1 | 2018 | 5 | 0.19 | Why? |
| Vulvar Diseases | 1 | 2019 | 38 | 0.19 | Why? |
| Panniculitis | 1 | 2018 | 13 | 0.19 | Why? |
| France | 13 | 2020 | 12074 | 0.19 | Why? |
| Papillomavirus Infections | 2 | 2018 | 861 | 0.19 | Why? |
| Leukemia, Myeloid | 1 | 2019 | 76 | 0.19 | Why? |
| Hypergammaglobulinemia | 1 | 2017 | 5 | 0.19 | Why? |
| Acute Generalized Exanthematous Pustulosis | 1 | 2020 | 96 | 0.18 | Why? |
| Carcinoma, Squamous Cell | 2 | 2018 | 902 | 0.18 | Why? |
| Scleroderma, Systemic | 2 | 2017 | 583 | 0.18 | Why? |
| Osteoarthropathy, Primary Hypertrophic | 1 | 2017 | 3 | 0.18 | Why? |
| Muir-Torre Syndrome | 1 | 2017 | 1 | 0.18 | Why? |
| Lichenoid Eruptions | 1 | 2018 | 22 | 0.18 | Why? |
| Sebaceous Gland Neoplasms | 1 | 2017 | 3 | 0.18 | Why? |
| Scrotum | 1 | 2018 | 48 | 0.18 | Why? |
| Ecthyma, Contagious | 1 | 2017 | 8 | 0.18 | Why? |
| Sunscreening Agents | 1 | 2019 | 63 | 0.18 | Why? |
| Fasciitis | 1 | 2017 | 6 | 0.18 | Why? |
| Epidermolysis Bullosa Acquisita | 1 | 2017 | 7 | 0.18 | Why? |
| Lymphoma, B-Cell, Marginal Zone | 1 | 2018 | 44 | 0.18 | Why? |
| Receptors, KIR2DL2 | 1 | 2017 | 4 | 0.18 | Why? |
| Bone Diseases, Metabolic | 1 | 2018 | 64 | 0.18 | Why? |
| Nephrogenic Fibrosing Dermopathy | 1 | 2017 | 7 | 0.18 | Why? |
| Scleredema Adultorum | 1 | 2017 | 6 | 0.18 | Why? |
| MAP Kinase Kinase 1 | 1 | 2017 | 14 | 0.18 | Why? |
| Scleromyxedema | 1 | 2017 | 10 | 0.18 | Why? |
| Skin Diseases, Infectious | 1 | 2019 | 77 | 0.18 | Why? |
| Organic Anion Transporters | 1 | 2017 | 40 | 0.18 | Why? |
| Lymphoma, Non-Hodgkin | 2 | 2019 | 403 | 0.18 | Why? |
| Germ-Line Mutation | 1 | 2018 | 86 | 0.17 | Why? |
| Complement C1q | 1 | 2017 | 31 | 0.17 | Why? |
| Paraproteinemias | 1 | 2018 | 61 | 0.17 | Why? |
| Adult | 38 | 2020 | 244371 | 0.17 | Why? |
| Lymphogranuloma Venereum | 1 | 2017 | 23 | 0.17 | Why? |
| Undifferentiated Connective Tissue Diseases | 1 | 2017 | 60 | 0.17 | Why? |
| Buschke-Lowenstein Tumor | 1 | 2016 | 3 | 0.17 | Why? |
| Histiocytosis, Langerhans-Cell | 1 | 2017 | 46 | 0.17 | Why? |
| Aspergillosis, Allergic Bronchopulmonary | 1 | 2017 | 38 | 0.17 | Why? |
| Carcinoma, Basal Cell | 1 | 2019 | 144 | 0.17 | Why? |
| Cellulitis | 1 | 2018 | 119 | 0.17 | Why? |
| Female | 49 | 2020 | 380317 | 0.17 | Why? |
| Lichen Planus | 1 | 2018 | 60 | 0.17 | Why? |
| Penis | 1 | 2017 | 101 | 0.17 | Why? |
| Genital Neoplasms, Male | 1 | 2016 | 14 | 0.17 | Why? |
| Churg-Strauss Syndrome | 1 | 2017 | 61 | 0.17 | Why? |
| Neoplastic Cells, Circulating | 1 | 2017 | 68 | 0.16 | Why? |
| Sentinel Lymph Node Biopsy | 1 | 2018 | 173 | 0.16 | Why? |
| Central Nervous System Neoplasms | 1 | 2017 | 88 | 0.16 | Why? |
| Synovitis | 1 | 2017 | 47 | 0.16 | Why? |
| Eye Neoplasms | 1 | 2017 | 71 | 0.16 | Why? |
| Biopsy, Needle | 4 | 2019 | 303 | 0.16 | Why? |
| Edema | 2 | 2017 | 333 | 0.16 | Why? |
| CTLA-4 Antigen | 1 | 2018 | 282 | 0.16 | Why? |
| Middle Aged | 41 | 2020 | 270681 | 0.16 | Why? |
| Antibodies, Monoclonal | 5 | 2018 | 8041 | 0.16 | Why? |
| Myelodysplastic Syndromes | 1 | 2019 | 261 | 0.16 | Why? |
| Polyarteritis Nodosa | 1 | 2015 | 25 | 0.16 | Why? |
| Neuralgia | 1 | 2017 | 99 | 0.16 | Why? |
| Tobacco Use | 1 | 2019 | 340 | 0.16 | Why? |
| Arylamine N-Acetyltransferase | 1 | 1995 | 15 | 0.16 | Why? |
| Arteritis | 1 | 2015 | 23 | 0.16 | Why? |
| Pemphigoid, Bullous | 1 | 2017 | 89 | 0.15 | Why? |
| Alopecia | 2 | 2019 | 351 | 0.15 | Why? |
| Proto-Oncogene Proteins B-raf | 1 | 2017 | 179 | 0.15 | Why? |
| Chlamydia trachomatis | 1 | 2017 | 172 | 0.15 | Why? |
| Ulcer | 1 | 2017 | 128 | 0.15 | Why? |
| Aged | 34 | 2020 | 215776 | 0.15 | Why? |
| Polyethylene Glycols | 2 | 2017 | 574 | 0.15 | Why? |
| Antigens, Neoplasm | 1 | 2017 | 230 | 0.15 | Why? |
| Acne Vulgaris | 1 | 2019 | 198 | 0.15 | Why? |
| Hypersensitivity, Immediate | 1 | 2017 | 134 | 0.15 | Why? |
| Keloid | 1 | 2014 | 10 | 0.14 | Why? |
| Dose-Response Relationship, Drug | 3 | 2019 | 3776 | 0.14 | Why? |
| Triamcinolone | 1 | 2014 | 24 | 0.14 | Why? |
| Mammaplasty | 1 | 2018 | 224 | 0.14 | Why? |
| Retrospective Studies | 24 | 2020 | 105322 | 0.14 | Why? |
| Mouth Diseases | 1 | 2018 | 193 | 0.14 | Why? |
| Prognosis | 11 | 2019 | 32490 | 0.14 | Why? |
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 1995 | 170 | 0.14 | Why? |
| Lymphoma | 2 | 2018 | 522 | 0.14 | Why? |
| Dermatology | 3 | 2020 | 1999 | 0.14 | Why? |
| Lymph Nodes | 2 | 2018 | 1060 | 0.14 | Why? |
| Aminoquinolines | 1 | 2014 | 63 | 0.14 | Why? |
| Eosinophilia | 1 | 2017 | 292 | 0.13 | Why? |
| Arthritis | 1 | 2018 | 288 | 0.13 | Why? |
| Carcinoma | 1 | 2017 | 256 | 0.13 | Why? |
| Porphyria Cutanea Tarda | 1 | 2013 | 8 | 0.13 | Why? |
| Remission Induction | 4 | 2018 | 950 | 0.13 | Why? |
| Erythema | 1 | 2018 | 400 | 0.13 | Why? |
| Pyridines | 1 | 2019 | 680 | 0.13 | Why? |
| Expert Testimony | 1 | 2017 | 658 | 0.13 | Why? |
| Myeloproliferative Disorders | 1 | 2018 | 507 | 0.13 | Why? |
| Sex Distribution | 5 | 2018 | 2083 | 0.13 | Why? |
| Stevens-Johnson Syndrome | 1 | 1995 | 129 | 0.13 | Why? |
| Diabetes Mellitus, Type 1 | 2 | 2018 | 1969 | 0.13 | Why? |
| Drug Eruptions | 1 | 2017 | 319 | 0.12 | Why? |
| Foot Dermatoses | 1 | 2014 | 112 | 0.12 | Why? |
| Flow Cytometry | 2 | 2018 | 2393 | 0.12 | Why? |
| Dermatologic Surgical Procedures | 1 | 2014 | 138 | 0.12 | Why? |
| Muscular Diseases | 1 | 2017 | 392 | 0.12 | Why? |
| T-Lymphocytes | 2 | 2021 | 6670 | 0.11 | Why? |
| Arthritis, Psoriatic | 1 | 2018 | 625 | 0.11 | Why? |
| Antibodies, Monoclonal, Humanized | 3 | 2019 | 9335 | 0.11 | Why? |
| Azetidines | 1 | 2017 | 722 | 0.11 | Why? |
| Treatment Failure | 1 | 2017 | 2106 | 0.11 | Why? |
| Colchicine | 2 | 2017 | 730 | 0.11 | Why? |
| Piperidines | 1 | 2017 | 795 | 0.11 | Why? |
| Autoimmunity | 1 | 2018 | 841 | 0.11 | Why? |
| DNA Mutational Analysis | 3 | 2018 | 581 | 0.11 | Why? |
| Age Distribution | 5 | 2018 | 3567 | 0.11 | Why? |
| Disease Progression | 6 | 2019 | 13580 | 0.11 | Why? |
| Tomography, X-Ray Computed | 1 | 2017 | 25144 | 0.11 | Why? |
| Immunohistochemistry | 4 | 2019 | 2275 | 0.10 | Why? |
| Immunotherapy | 3 | 2019 | 2421 | 0.10 | Why? |
| Autoantibodies | 2 | 2018 | 2094 | 0.10 | Why? |
| Anticonvulsants | 1 | 1995 | 634 | 0.10 | Why? |
| T-Lymphocyte Subsets | 1 | 2017 | 1387 | 0.10 | Why? |
| Ultraviolet Rays | 1 | 2019 | 1272 | 0.10 | Why? |
| Chronic Disease | 6 | 2018 | 5139 | 0.09 | Why? |
| Early Diagnosis | 1 | 2018 | 2443 | 0.09 | Why? |
| Chronic Pain | 1 | 2017 | 736 | 0.09 | Why? |
| Protein Kinase Inhibitors | 1 | 2018 | 1585 | 0.09 | Why? |
| Delayed Diagnosis | 1 | 2018 | 1529 | 0.09 | Why? |
| Bronchiolitis Obliterans | 2 | 2019 | 86 | 0.09 | Why? |
| Lupus Erythematosus, Systemic | 1 | 2019 | 1380 | 0.09 | Why? |
| Exanthema | 1 | 2018 | 1097 | 0.09 | Why? |
| Clobetasol | 2 | 2017 | 25 | 0.09 | Why? |
| Lasers, Gas | 2 | 2017 | 21 | 0.09 | Why? |
| Kaplan-Meier Estimate | 4 | 2019 | 4260 | 0.09 | Why? |
| Homosexuality, Male | 1 | 2017 | 1158 | 0.09 | Why? |
| Treatment Outcome | 13 | 2019 | 51732 | 0.09 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 1261 | 0.08 | Why? |
| Drug Administration Schedule | 3 | 2019 | 2324 | 0.08 | Why? |
| Antimetabolites, Antineoplastic | 1 | 2008 | 99 | 0.08 | Why? |
| Quality of Life | 2 | 2019 | 9820 | 0.08 | Why? |
| CD3 Complex | 2 | 2019 | 237 | 0.08 | Why? |
| Pyrazoles | 1 | 2017 | 1791 | 0.08 | Why? |
| Mutation | 2 | 2017 | 12376 | 0.08 | Why? |
| Severity of Illness Index | 13 | 2019 | 48226 | 0.08 | Why? |
| Follow-Up Studies | 7 | 2018 | 17020 | 0.08 | Why? |
| Psoriasis | 2 | 2018 | 1739 | 0.08 | Why? |
| Sulfonamides | 1 | 1995 | 1294 | 0.08 | Why? |
| Time Factors | 7 | 2019 | 31397 | 0.08 | Why? |
| Early Detection of Cancer | 1 | 2018 | 1956 | 0.08 | Why? |
| Genetic Markers | 2 | 2017 | 318 | 0.08 | Why? |
| Hematologic Neoplasms | 1 | 2019 | 2105 | 0.07 | Why? |
| Lymphopenia | 1 | 2018 | 2669 | 0.07 | Why? |
| Lymphatic Metastasis | 2 | 2018 | 537 | 0.07 | Why? |
| Aged, 80 and over | 14 | 2020 | 88759 | 0.07 | Why? |
| Antirheumatic Agents | 1 | 2020 | 3023 | 0.07 | Why? |
| Antimalarials | 1 | 2017 | 2505 | 0.07 | Why? |
| Interferon-alpha | 2 | 2017 | 1442 | 0.07 | Why? |
| Thromboembolism | 1 | 2018 | 2101 | 0.07 | Why? |
| Young Adult | 11 | 2020 | 93724 | 0.07 | Why? |
| Dyspnea | 1 | 2018 | 3847 | 0.07 | Why? |
| Prednisone | 2 | 2019 | 652 | 0.07 | Why? |
| Mobile Applications | 1 | 2020 | 3032 | 0.07 | Why? |
| Aluminum | 1 | 2004 | 71 | 0.07 | Why? |
| Lymphocytes | 2 | 2015 | 3056 | 0.07 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2019 | 4545 | 0.06 | Why? |
| Excipients | 1 | 2004 | 118 | 0.06 | Why? |
| Incidence | 7 | 2018 | 25622 | 0.06 | Why? |
| Statistics, Nonparametric | 2 | 2018 | 1008 | 0.06 | Why? |
| Hydroxychloroquine | 4 | 2020 | 12447 | 0.06 | Why? |
| Neutrophils | 1 | 2019 | 5476 | 0.06 | Why? |
| Recurrence | 3 | 2021 | 3675 | 0.06 | Why? |
| Immunosuppressive Agents | 2 | 2018 | 6331 | 0.06 | Why? |
| Syndrome | 2 | 2018 | 1310 | 0.06 | Why? |
| Aging | 1 | 2019 | 3581 | 0.06 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.06 | Why? |
| Signal Transduction | 1 | 2019 | 7207 | 0.06 | Why? |
| Hyperplasia | 2 | 2017 | 204 | 0.06 | Why? |
| Pneumonia, Viral | 5 | 2020 | 243684 | 0.06 | Why? |
| Registries | 2 | 2018 | 12327 | 0.06 | Why? |
| Immunologic Factors | 3 | 2018 | 4206 | 0.06 | Why? |
| Coronavirus Infections | 5 | 2020 | 253789 | 0.06 | Why? |
| Immunocompetence | 1 | 2002 | 280 | 0.05 | Why? |
| Glucocorticoids | 4 | 2017 | 4431 | 0.05 | Why? |
| Pyrin | 1 | 2019 | 15 | 0.05 | Why? |
| Pandemics | 8 | 2021 | 389249 | 0.05 | Why? |
| Adolescent | 7 | 2020 | 86841 | 0.05 | Why? |
| Retreatment | 1 | 2019 | 186 | 0.05 | Why? |
| Chickenpox | 1 | 2002 | 194 | 0.05 | Why? |
| Cytokines | 2 | 2018 | 15010 | 0.05 | Why? |
| Survival Rate | 3 | 2018 | 9206 | 0.05 | Why? |
| Leukocyte Common Antigens | 1 | 2019 | 101 | 0.05 | Why? |
| Risk Factors | 8 | 2019 | 71621 | 0.05 | Why? |
| Validation Studies as Topic | 1 | 2018 | 121 | 0.05 | Why? |
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 2017 | 3 | 0.05 | Why? |
| Skin Aging | 1 | 2019 | 55 | 0.04 | Why? |
| Predictive Value of Tests | 3 | 2018 | 9537 | 0.04 | Why? |
| Practice Guidelines as Topic | 2 | 2020 | 15421 | 0.04 | Why? |
| CD4-CD8 Ratio | 1 | 2019 | 235 | 0.04 | Why? |
| Ankle | 1 | 2018 | 66 | 0.04 | Why? |
| Leukemia, Myelomonocytic, Juvenile | 1 | 2017 | 27 | 0.04 | Why? |
| Fatal Outcome | 1 | 2008 | 3438 | 0.04 | Why? |
| Intramolecular Oxidoreductases | 1 | 2017 | 38 | 0.04 | Why? |
| Premedication | 1 | 2017 | 40 | 0.04 | Why? |
| Mass Screening | 1 | 2018 | 8005 | 0.04 | Why? |
| Phenotype | 3 | 2019 | 4037 | 0.04 | Why? |
| Proctitis | 1 | 2017 | 16 | 0.04 | Why? |
| Cicatrix | 1 | 2019 | 129 | 0.04 | Why? |
| Europe | 3 | 2020 | 12702 | 0.04 | Why? |
| Receptors, Cytokine | 1 | 2017 | 75 | 0.04 | Why? |
| Retinoids | 1 | 2017 | 43 | 0.04 | Why? |
| Cryotherapy | 1 | 2017 | 31 | 0.04 | Why? |
| Cohort Studies | 5 | 2020 | 36005 | 0.04 | Why? |
| Risk Assessment | 5 | 2019 | 25439 | 0.04 | Why? |
| Electrons | 1 | 2017 | 53 | 0.04 | Why? |
| Herpes Zoster | 1 | 2002 | 331 | 0.04 | Why? |
| Bacterial Typing Techniques | 1 | 2018 | 273 | 0.04 | Why? |
| Food Handling | 1 | 2017 | 103 | 0.04 | Why? |
| Clone Cells | 1 | 2017 | 312 | 0.04 | Why? |
| Diabetes Mellitus, Type 2 | 1 | 2018 | 6166 | 0.04 | Why? |
| Sampling Studies | 1 | 2018 | 386 | 0.04 | Why? |
| Homozygote | 1 | 2017 | 230 | 0.04 | Why? |
| Precancerous Conditions | 1 | 2017 | 108 | 0.04 | Why? |
| Electrocoagulation | 1 | 2017 | 72 | 0.04 | Why? |
| Debridement | 1 | 2017 | 172 | 0.04 | Why? |
| Neoplastic Stem Cells | 1 | 2017 | 120 | 0.04 | Why? |
| Sheep | 1 | 2017 | 420 | 0.04 | Why? |
| Physical Exertion | 1 | 2017 | 176 | 0.04 | Why? |
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2017 | 203 | 0.04 | Why? |
| Proportional Hazards Models | 2 | 2019 | 6543 | 0.04 | Why? |
| Genitalia, Male | 1 | 2017 | 107 | 0.04 | Why? |
| Acetylation | 1 | 1995 | 124 | 0.04 | Why? |
| Cell Separation | 1 | 2017 | 270 | 0.04 | Why? |
| Foot Orthoses | 1 | 2014 | 3 | 0.04 | Why? |
| Phototherapy | 1 | 2017 | 138 | 0.04 | Why? |
| Keratolytic Agents | 1 | 2014 | 16 | 0.04 | Why? |
| Drug Therapy, Combination | 2 | 2019 | 7268 | 0.04 | Why? |
| Hospitals, University | 2 | 2018 | 4173 | 0.04 | Why? |
| Salvage Therapy | 1 | 2017 | 417 | 0.04 | Why? |
| Watchful Waiting | 1 | 2017 | 276 | 0.04 | Why? |
| Adrenal Cortex Hormones | 3 | 2018 | 6537 | 0.04 | Why? |
| Serogroup | 1 | 2017 | 510 | 0.03 | Why? |
| Organ Specificity | 1 | 2019 | 1070 | 0.03 | Why? |
| Adalimumab | 1 | 2018 | 389 | 0.03 | Why? |
| Drug Administration Routes | 1 | 2014 | 106 | 0.03 | Why? |
| Uroporphyrins | 1 | 2013 | 1 | 0.03 | Why? |
| Gout Suppressants | 1 | 2014 | 54 | 0.03 | Why? |
| Hypertrichosis | 1 | 2013 | 5 | 0.03 | Why? |
| Genetic Association Studies | 1 | 2017 | 559 | 0.03 | Why? |
| Survival Analysis | 2 | 2018 | 7592 | 0.03 | Why? |
| Pain Measurement | 1 | 2017 | 533 | 0.03 | Why? |
| Cardiovascular Diseases | 1 | 2019 | 11497 | 0.03 | Why? |
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2019 | 581 | 0.03 | Why? |
| Laser Therapy | 1 | 2016 | 158 | 0.03 | Why? |
| Sarcoidosis | 1 | 2017 | 271 | 0.03 | Why? |
| Biological Factors | 1 | 2017 | 276 | 0.03 | Why? |
| Hematopoietic Stem Cell Transplantation | 2 | 2017 | 2426 | 0.03 | Why? |
| Age Factors | 3 | 2019 | 21039 | 0.03 | Why? |
| Hyperpigmentation | 1 | 2013 | 42 | 0.03 | Why? |
| Cell Differentiation | 1 | 2019 | 1338 | 0.03 | Why? |
| Healthy Volunteers | 1 | 2019 | 1444 | 0.03 | Why? |
| Radiotherapy | 1 | 2018 | 608 | 0.03 | Why? |
| Antibody-Dependent Cell Cytotoxicity | 1 | 2014 | 349 | 0.03 | Why? |
| Nitriles | 1 | 2017 | 1053 | 0.03 | Why? |
| Immunophenotyping | 1 | 2017 | 1290 | 0.03 | Why? |
| Phlebotomy | 1 | 2013 | 131 | 0.03 | Why? |
| Antigens, CD | 1 | 2017 | 984 | 0.03 | Why? |
| Datasets as Topic | 1 | 2018 | 1404 | 0.03 | Why? |
| Single-Blind Method | 1 | 2015 | 1283 | 0.03 | Why? |
| Steroids | 1 | 2017 | 904 | 0.03 | Why? |
| Genetic Predisposition to Disease | 2 | 2017 | 4027 | 0.03 | Why? |
| Physical Examination | 1 | 2017 | 755 | 0.03 | Why? |
| Telemedicine | 2 | 2020 | 25032 | 0.03 | Why? |
| Islam | 1 | 2017 | 545 | 0.03 | Why? |
| Infection Control | 1 | 2020 | 23131 | 0.03 | Why? |
| Sex Factors | 2 | 2018 | 11014 | 0.03 | Why? |
| Area Under Curve | 1 | 2018 | 2564 | 0.03 | Why? |
| Drug Overdose | 1 | 2017 | 583 | 0.03 | Why? |
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 1014 | 0.03 | Why? |
| Virulence | 1 | 2017 | 2172 | 0.02 | Why? |
| Rituximab | 1 | 2017 | 1096 | 0.02 | Why? |
| Pyrimidines | 1 | 2017 | 1557 | 0.02 | Why? |
| Molecular Targeted Therapy | 1 | 2019 | 1579 | 0.02 | Why? |
| Program Evaluation | 1 | 2018 | 1929 | 0.02 | Why? |
| Radiography | 1 | 2017 | 1576 | 0.02 | Why? |
| Carbon Dioxide | 1 | 2016 | 917 | 0.02 | Why? |
| Magnetic Resonance Imaging | 2 | 2017 | 6551 | 0.02 | Why? |
| Nucleocapsid Proteins | 1 | 2021 | 3120 | 0.02 | Why? |
| Medication Adherence | 1 | 2019 | 1270 | 0.02 | Why? |
| Activities of Daily Living | 1 | 2017 | 1530 | 0.02 | Why? |
| Pain Management | 1 | 2017 | 854 | 0.02 | Why? |
| Precision Medicine | 1 | 2019 | 1477 | 0.02 | Why? |
| Anti-Inflammatory Agents | 2 | 2017 | 6153 | 0.02 | Why? |
| Biomarkers, Tumor | 1 | 2017 | 1314 | 0.02 | Why? |
| Tumor Necrosis Factor-alpha | 1 | 2018 | 2483 | 0.02 | Why? |
| Combined Modality Therapy | 1 | 2017 | 3395 | 0.02 | Why? |
| Prisons | 1 | 2017 | 980 | 0.02 | Why? |
| Immune System | 1 | 2017 | 1479 | 0.02 | Why? |
| Child, Preschool | 3 | 2020 | 36283 | 0.02 | Why? |
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 1573 | 0.02 | Why? |
| Cost of Illness | 1 | 2017 | 1903 | 0.02 | Why? |
| Anti-Bacterial Agents | 2 | 2018 | 10083 | 0.02 | Why? |
| Cell Line, Tumor | 1 | 2014 | 3608 | 0.02 | Why? |
| ROC Curve | 1 | 2018 | 6024 | 0.02 | Why? |
| Genotype | 2 | 1995 | 4697 | 0.02 | Why? |
| Alcoholism | 1 | 2013 | 691 | 0.02 | Why? |
| Biomarkers | 2 | 2019 | 23361 | 0.02 | Why? |
| Patient Satisfaction | 1 | 2018 | 2517 | 0.02 | Why? |
| Immunologic Memory | 1 | 2017 | 3362 | 0.02 | Why? |
| International Cooperation | 1 | 2018 | 3436 | 0.02 | Why? |
| Australia | 1 | 2018 | 6306 | 0.02 | Why? |
| Japan | 1 | 2018 | 6653 | 0.02 | Why? |
| Adjuvants, Immunologic | 1 | 2014 | 1709 | 0.02 | Why? |
| Transcriptome | 1 | 2017 | 3466 | 0.02 | Why? |
| Referral and Consultation | 1 | 2020 | 4816 | 0.02 | Why? |
| Spinal Puncture | 1 | 1984 | 95 | 0.02 | Why? |
| Comorbidity | 2 | 2018 | 34796 | 0.02 | Why? |
| Animals | 3 | 2018 | 78931 | 0.02 | Why? |
| Logistic Models | 1 | 2018 | 9089 | 0.02 | Why? |
| Complement C1 Inactivator Proteins | 1 | 1982 | 11 | 0.02 | Why? |
| Chloroquine | 1 | 2017 | 3152 | 0.01 | Why? |
| Consensus | 1 | 2017 | 6345 | 0.01 | Why? |
| Child | 3 | 2020 | 70012 | 0.01 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2019 | 5837 | 0.01 | Why? |
| Lymphoproliferative Disorders | 1 | 1982 | 110 | 0.01 | Why? |
| Databases, Factual | 1 | 2015 | 6248 | 0.01 | Why? |
| Angioedema | 1 | 1982 | 111 | 0.01 | Why? |
| Immunocompromised Host | 1 | 2016 | 5150 | 0.01 | Why? |
| Case-Control Studies | 1 | 2018 | 17671 | 0.01 | Why? |
| Postoperative Complications | 1 | 2017 | 5861 | 0.01 | Why? |
| Vaccination | 1 | 2004 | 19050 | 0.01 | Why? |
| Liver Diseases | 1 | 2013 | 2698 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2017 | 22971 | 0.01 | Why? |
| Mice | 1 | 2014 | 21357 | 0.01 | Why? |
| Prospective Studies | 1 | 2018 | 43301 | 0.01 | Why? |
| Disease Outbreaks | 1 | 2021 | 27595 | 0.01 | Why? |
| United States | 1 | 2018 | 46150 | 0.01 | Why? |
| Gene Rearrangement, T-Lymphocyte | 1 | 1990 | 2 | 0.01 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 37182 | 0.01 | Why? |
| HIV Infections | 1 | 2016 | 11620 | 0.01 | Why? |
| DNA, Neoplasm | 1 | 1990 | 56 | 0.01 | Why? |
| Intracranial Pressure | 1 | 1984 | 90 | 0.00 | Why? |
| Meningitis | 1 | 1984 | 163 | 0.00 | Why? |
| Cerebral Infarction | 1 | 1984 | 245 | 0.00 | Why? |
| Risk | 1 | 1984 | 5288 | 0.00 | Why? |
| Acute Disease | 1 | 1984 | 6029 | 0.00 | Why? |